Evoke Pharma Q2 Earnings: Revenue at $3.75M, EPS of 62c

Evoke Pharma reported Q2 EPS of 62c, a significant improvement from 93c last year. Revenue increased to $3.75M, up 47% YoY, driven by accelerating demand from physicians and patients. The company's CEO said the results demonstrate the commercial strength of GIMOTI, its treatment for diabetic gastroparesis, and the precision of its execution.

Evoke Pharma (NASDAQ: EVOK) reported robust financial results for the second quarter of 2025, showcasing a significant improvement in earnings per share (EPS) and substantial revenue growth driven by the commercial success of its gastroparesis treatment, GIMOTI. The company's net product sales surged by 47% year-over-year (YoY) to $3.8 million, a testament to the accelerating demand from physicians and patients for its nasal spray formulation of metoclopramide.

The EPS for Q2 2025 was reported at 62 cents per share, a notable improvement from the 93 cents per share reported in the same period last year. This improvement was achieved despite a net loss of $1.6 million, or $0.62 per share, compared to a net loss of $1.3 million, or $0.93 per share, in Q2 2024. The increase in net loss was primarily attributed to higher operating expenses, which grew to $5.3 million from $3.8 million, driven by increased profit-sharing payments to EVERSANA and higher professional fees.

Evoke Pharma's CEO, Matt D'Onofrio, attributed the strong performance to the commercial strength of GIMOTI and the precision of the company's execution. The company's net product sales were bolstered by a 20% increase in new prescribers and a stable 70% refill rate, indicating strong patient retention and consistent therapeutic benefit. The company's cash position remains robust, with $12.1 million in cash and cash equivalents, providing a runway into Q3 2026 based on current burn rates and projected GIMOTI sales.

The company has maintained its full-year 2025 net product sales guidance of approximately $16 million, which would represent a potential 60% increase over 2024. This growth is expected to be driven by continued prescription growth, expanded pharmacy access, and the ongoing adoption of GIMOTI. Despite the revenue growth, Evoke Pharma acknowledges potential headwinds, including payer dynamics and macroeconomic factors, which could impact its outlook.

In conclusion, Evoke Pharma's Q2 2025 financial results demonstrate the company's growing commercial traction with GIMOTI and its ability to execute its commercial strategy effectively. The company's strong cash position and confident outlook position it well for continued growth in the coming quarters.

References:
[1] https://www.stocktitan.net/news/EVOK/evoke-pharma-reports-second-quarter-2025-financial-results-and-ufl689mzps3p.html